Clarivate Acquires Bioinfogate For Undisclosed Terms To Expand Drug R&D Intelligence

August 4, 2021 7:17 AM | 1 min read |

Clarivate PLC CLVT acquired Bioinfogate, an analytics solutions provider in the life sciences and producer of the OFF-X portal.
The financial terms of the transaction remain undisclosed.
The acquisition of Bioinfogate will fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D.
With previously acquired Cortellis, OFF-X will provide critical translational safety intelligence alongside a robust drug pipeline and clinical research information.
Beyond Cortellis, OFF-X will strengthen other Clarivate products and services, including the Web of Science, the publisher-independent global citation database.
Clarivate held $2.6 billion in cash and equivalents as of Jun. 30.
Price action: CLVT shares closed higher by 1.53% at $23.16 on Tuesday.

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.